Viyash Scientific unveiled ambitious 2032 targets, aiming for $1 billion revenue and $250 million EBITDA. The company reported strong post-merger EBITDA growth and outlined strategic acquisitions, including one in Italy.
Viyash Scientific Eyes $1 Billion Revenue by 2032
FY26 Revenue: 34,203 INR MN
FY26 EBITDA: 7,025 INR MN
Reader Takeaway: Strong margin growth and clear long-term targets are positives, but regulatory reliance is a watch point.
What just happened
Viyash Scientific announced ambitious long-term aspirations, targeting approximately $1 billion in revenue and $250 million in EBITDA by 2032. For FY26, the company projects revenues of 34,203 INR million and EBITDA of 7,025 INR million, reflecting a 13% annualized revenue growth and a significant 60% annualized EBITDA growth from FY24 to FY26.
Why this matters
These targets indicate a strong focus on scaling operations, improving profitability, and strategic expansion. The company highlighted successful integration of functions post-merger, combined procurement, and a new acquisition, Bio For Life in Italy, to boost its companion animal segment.
The backstory
In FY24, Viyash Scientific reported revenue of 26,807 INR million and EBITDA of 2,739 INR million. The company has consistently shown top-line growth and a substantial increase in EBITDA, signaling improved operating leverage and successful cost management.
What changes now
The company is actively pursuing growth through organic means and strategic acquisitions. The Italy acquisition is expected to grant access to the companion animal market and an 85-90 product portfolio. The focus is on high-potent API and complex formulations, suggesting a shift towards higher-margin products.
Risks to watch
A key concern is the company's reliance on regulatory audits, such as USFDA and EU-GMP. Any adverse outcomes from these audits could potentially impact operations. Additionally, future growth is contingent on market trends, particularly genericization within the animal health sector.
Peer comparison
While specific peer data was not provided in the filing, Viyash Scientific's diversified revenue mix across Animal Formulations (45%), API + CDMO (43%), and Human Formulations (12%) for FY26 suggests a balanced business model. This diversification can mitigate risks associated with any single segment.
Context metrics (time-bound)
- FY26 Projected Revenue: 34,203 INR MN
- FY26 Projected EBITDA: 7,025 INR MN
- FY24 Revenue: 26,807 INR MN
- FY24 EBITDA: 2,739 INR MN
- Annualized Revenue Growth (FY24-FY26): 13%
- Annualized EBITDA Growth (FY24-FY26): 60%
- 2032 Aspiration Revenue: ~$1 Billion
- 2032 Aspiration EBITDA: ~$250 Million
What to track next
Investors should monitor the successful integration and performance of the Bio For Life acquisition in Italy, the realization of synergy benefits from the merger, and the company's ability to meet its ambitious 2032 growth targets. Continued EBITDA margin expansion will be a key indicator.